Literature DB >> 10653376

An association between cytomegalovirus infection and chronic rejection after liver transplantation.

P C Evans1, A Soin, T G Wreghitt, C J Taylor, D G Wight, G J Alexander.   

Abstract

BACKGROUND: Previous studies suggest a link between cytomegalovirus (CMV) infection and chronic rejection. Since these studies, more sophisticated diagnostic methods with high sensitivity and specificity for CMV have been developed and effective therapy/prophylaxis for CMV is now available. We sought CMV prospectively by polymerase chain reaction of serum and urine and by conventional methods in a group of 33 patients undergoing 57 transplants during 1993 or 1994, selected from a larger series. There were 13 grafts lost to chronic rejection. The remaining 44 grafts that did not develop chronic rejection served as controls and comprised 15 successful primary grafts, 15 second transplants, 8 third transplants, and 6 primary grafts that were lost for reasons other than chronic rejection.
RESULTS: The combination donor CMV antibody negative with recipient antibody positive and the duration of CMV infection >30 days were associated with an increased relative risk of chronic rejection. In contrast, the presence of CMV infection alone, symptomatic CMV infection, the detection of CMV by PCR of serum or urine, and the peak/cumulative viral load were not predictive. CMV infection occurred earlier in those undergoing a second transplant for chronic rejection than for those undergoing a second transplant for other reasons. In addition, a human leukocyte antigen B mismatch was associated with prolonged CMV infection.
CONCLUSION: These data are consistent with the hypothesis that prolonged subclinical cytomegalovirus infection is associated with an increased risk of chronic rejection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10653376     DOI: 10.1097/00007890-200001150-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay.

Authors:  Karine Hadaya; Werner Wunderli; Christelle Deffernez; Pierre-Yves Martin; Gilles Mentha; Isabelle Binet; Luc Perrin; Laurent Kaiser
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

Review 2.  Cytomegalovirus and the aging population.

Authors:  V C Emery
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Correlation and clinical utility of pp65 antigenemia and quantitative polymerase chain reaction assays for detection of cytomegalovirus in pediatric renal transplant patients.

Authors:  Brian Rha; David Redden; Mark Benfield; Fred Lakeman; Richard J Whitley; Masako Shimamura
Journal:  Pediatr Transplant       Date:  2012-06-13

4.  The life cycle and pathogenesis of human cytomegalovirus infection: lessons from proteomics.

Authors:  Pierre M Jean Beltran; Ileana M Cristea
Journal:  Expert Rev Proteomics       Date:  2014-10-18       Impact factor: 3.940

Review 5.  Immunobiology of human cytomegalovirus: from bench to bedside.

Authors:  Tania Crough; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

Review 6.  Adverse effects of immunosuppression in pediatric solid organ transplantation.

Authors:  Kristine S Schonder; George V Mazariegos; Robert J Weber
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

7.  Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays.

Authors:  Angela M Caliendo; Kirsten St George; Jessica Allega; Arlene C Bullotta; Lisa Gilbane; Charles R Rinaldo
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

8.  Prognostic factors for the evolution and reversibility of chronic rejection in pediatric liver transplantation.

Authors:  Ana Cristina Aoun Tannuri; Fabiana Lima; Evandro Sobroza de Mello; Ryan Yukimatsu Tanigawa; Uenis Tannuri
Journal:  Clinics (Sao Paulo)       Date:  2016-04       Impact factor: 2.365

9.  Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.

Authors:  Lior Nesher; Dimpy P Shah; Ella J Ariza-Heredia; Jacques M Azzi; Hala K Siddiqui; Shasank S Ghantoji; Lisa Y Marsh; Lamprinos Michailidis; George Makedonas; Katy Rezvani; Elizabeth J Shpall; Roy F Chemaly
Journal:  J Infect Dis       Date:  2016-02-11       Impact factor: 5.226

Review 10.  Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies.

Authors:  Sang Hoon Han
Journal:  Infect Chemother       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.